FMP
Cellectar Biosciences, Inc.
CLRB
NASDAQ
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
0.279 USD
0.0064 (2.29%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
10.6B
7.89B
7.41B
9.18B
8.77B
13.93B
16.23B
18.92B
22.06B
25.71B
Total Cash %
69.25
41.8
33.31
36.58
31.14
42.42
42.42
42.42
42.42
Receivables
2.65B
3.01B
3.42B
4.06B
3.77B
5.13B
5.98B
6.98B
8.13B
9.48B
Receivables %
17.29
15.92
15.4
16.18
13.4
15.64
15.64
15.64
15.64
Inventories
-
-
-
-
-
-
-
-
-
-
Inventories %
-
-
-
-
-
-
-
-
-
Payable
527M
738M
926M
834M
929M
1.19B
1.39B
1.62B
1.89B
2.2B
Payable %
3.44
3.91
4.16
3.32
3.3
3.63
3.63
3.63
3.63
Cap Ex
-708M
-814M
-1.1B
-371M
-474M
-1.12B
-1.3B
-1.52B
-1.77B
-2.06B
Cap Ex %
-4.63
-4.31
-4.93
-1.48
-1.68
-3.41
-3.41
-3.41
-3.41
